National Research (NASDAQ: NRCIA) is one of 99 publicly-traded companies in the “Business Support Services” industry, but how does it contrast to its rivals? We will compare National Research to related businesses based on the strength of its profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.
Valuation and Earnings
This table compares National Research and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|National Research||$109.38 million||$20.51 million||72.00|
|National Research Competitors||$1.27 billion||$103.59 million||1,277.68|
National Research’s rivals have higher revenue and earnings than National Research. National Research is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
25.2% of National Research shares are held by institutional investors. Comparatively, 62.6% of shares of all “Business Support Services” companies are held by institutional investors. 37.5% of National Research shares are held by company insiders. Comparatively, 12.7% of shares of all “Business Support Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for National Research and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|National Research Competitors||717||2017||2768||68||2.39|
National Research currently has a consensus target price of $44.00, suggesting a potential upside of 22.22%. As a group, “Business Support Services” companies have a potential upside of 4.06%. Given National Research’s higher probable upside, analysts clearly believe National Research is more favorable than its rivals.
National Research pays an annual dividend of $0.40 per share and has a dividend yield of 1.1%. National Research pays out 80.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Business Support Services” companies pay a dividend yield of 1.1% and pay out 26.0% of their earnings in the form of a dividend.
Volatility & Risk
National Research has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, National Research’s rivals have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.
This table compares National Research and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|National Research Competitors||-30.02%||-18.23%||1.35%|
National Research rivals beat National Research on 8 of the 15 factors compared.
National Research Company Profile
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions and physician engagement. NRC Health partners with clients across the range of healthcare services. The Company’s clients range from integrated health systems and post-acute providers, such as home health, long-term care and hospice, to payer organizations. NRC Health’s portfolio of solutions is designed to help healthcare companies.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.